Form 8-K - Current report:
SEC Accession No. 0001493152-24-003131
Filing Date
2024-01-22
Accepted
2024-01-22 08:45:38
Documents
14
Period of Report
2024-01-18
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 50763
2 ex99-1.htm EX-99.1 32732
3 ex99-1_001.jpg GRAPHIC 19182
  Complete submission text file 0001493152-24-003131.txt   290665

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE rspi-20240118.xsd EX-101.SCH 3018
5 XBRL LABEL FILE rspi-20240118_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE rspi-20240118_pre.xml EX-101.PRE 22361
8 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3080
Mailing Address 126 VALLEY ROAD SUITE C GLEN ROCK NJ 07452
Business Address 126 VALLEY ROAD SUITE C GLEN ROCK NJ 07452 (201) 444-4947
RespireRx Pharmaceuticals Inc. (Filer) CIK: 0000849636 (see all company filings)

EIN.: 330303583 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-16467 | Film No.: 24547185
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)